Differentiate between 510(k) clearance and PMA in the US regulatory pathway.

• A. 510(k) requires substantial evidence of safety and effectiveness via clinical data.
• B. 510(k) demonstrates substantial equivalence to a predicate device, generally for moderate-risk devices; PMA requires substantial evidence of safety and effectiveness via clinical data.
• C. 510(k) is for high-risk devices; PMA for low-risk devices.
• D. 510(k) and PMA are interchangeable.

Answer: (B)

When a medical device is prepared for FDA clearance, the path chosen depends on its risk level and the kind of evidence required. The 510(k) route is used for many moderate-risk devices and relies on showing substantial equivalence to a predicate device already legally marketed. This means the new device has the same intended use and similar technological characteristics, or the FDA determines it remains safe and effective despite differences. Clinical trials are not always needed; bench testing, biocompatibility, and other performance data often suffice.

For high-risk devices, a premarket approval is required, and you must provide substantial evidence of safety and effectiveness, usually from well-controlled clinical data. This path also involves detailed manufacturing information, labeling, and post-market plans.

So, the best description is that the 510(k) demonstrates substantial equivalence to a predicate device, generally for moderate-risk devices; PMA requires substantial evidence of safety and effectiveness via clinical data. The other statements don’t fit because 510(k) doesn’t always require clinical data, risk classifications differ, and the two pathways are not interchangeable.